Group 1 - Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) has experienced a significant increase of approximately 28% since being rated as a "Buy" in February 2025 [1] - The focus of the analysis is on the company's position in the genetic obesity market, highlighting its potential for growth and investment opportunities [1] - The author emphasizes the importance of learning from both investment successes and failures, indicating a long-term commitment to research and analysis in the healthcare sector [1] Group 2 - The article reflects a personal investment in Rhythm Pharmaceuticals, indicating a beneficial long position in the shares [2] - The author expresses a commitment to sharing insights and experiences related to investing, particularly in healthcare stocks, which may provide valuable context for potential investors [1][2] - The analysis is based on years of focused research, suggesting a depth of knowledge regarding the company's operations and market dynamics [1]